These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. LAG3 is an independent prognostic biomarker and potential target for immune checkpoint inhibitors in malignant pleural mesothelioma: a retrospective study. Arimura K, Hiroshima K, Nagashima Y, Nakazawa T, Ogihara A, Orimo M, Sato Y, Katsura H, Kanzaki M, Kondo M, Tagaya E. BMC Cancer; 2023 Dec 07; 23(1):1206. PubMed ID: 38062416 [Abstract] [Full Text] [Related]
4. [Expression and clinical significance of COL1A1 and COL1A2 genes in malignant pleural mesothelioma tissues]. Li B, Pu YQ, Li ZL, Zhao Y, Zi JJ, Xiong W. Zhonghua Lao Dong Wei Sheng Zhi Ye Bing Za Zhi; 2022 Jul 20; 40(7):487-494. PubMed ID: 35915937 [Abstract] [Full Text] [Related]
5. Functional Analysis of the Adrenomedullin Pathway in Malignant Pleural Mesothelioma. Greillier L, Tounsi A, Berenguer-Daizé C, Dussault N, Delfino C, Benyahia Z, Cayol M, Mabrouk K, Garcia S, Martin PM, Barlesi F, Ouafik L. J Thorac Oncol; 2016 Jan 20; 11(1):94-107. PubMed ID: 26762744 [Abstract] [Full Text] [Related]
12. Inhibition of yes-associated protein down-regulates PD-L1 (CD274) expression in human malignant pleural mesothelioma. Hsu PC, Miao J, Wang YC, Zhang WQ, Yang YL, Wang CW, Yang CT, Huang Z, You J, Xu Z, Jablons DM, You L. J Cell Mol Med; 2018 Jun 20; 22(6):3139-3148. PubMed ID: 29575535 [Abstract] [Full Text] [Related]
14. CD157 enhances malignant pleural mesothelioma aggressiveness and predicts poor clinical outcome. Ortolan E, Giacomino A, Martinetto F, Morone S, Lo Buono N, Ferrero E, Scagliotti G, Novello S, Orecchia S, Ruffini E, Rapa I, Righi L, Volante M, Funaro A. Oncotarget; 2014 Aug 15; 5(15):6191-205. PubMed ID: 25026285 [Abstract] [Full Text] [Related]